Nai-Kong V. Cheung, MD, PhD

Head, Neuroblastoma Program; Enid A. Haupt Chair in Pediatric Oncology
Nai-Kong V. Cheung, MD, PhD -- Head, Neuroblastoma Program; Enid A. Haupt Chair in Pediatric Oncology

I am a pediatric oncologist who specializes in immunologic approaches for the diagnosis and treatment of pediatric cancers. My main focus is the treatment of neuroblastoma, a tumor that arises from primitive cells of the sympathetic nervous system and that primarily affects young children.

My colleagues and I have developed multi-modality therapies, which include surgery, chemotherapy, radiation therapy, isotretinoin (a vitamin A derivative), and more importantly, targeted therapy with monoclonal antibodies. These treatment strategies have dramatically improved the survival for our patients with metastatic neuroblastoma. Today, more than 50 percent of these patients treated at Memorial Sloan Kettering survive the disease, compared to fewer than 5 percent in the 1980s. In fact, immunotherapy has now become the standard of care for patients with metastatic neuroblastoma. Moreover, localized neuroblastoma is curable today, and many patients with can be treated effectively with surgery alone.

Appointments for New Patients
Clinical Expertise

Pediatric Oncology; Neuroblastoma and Developmental Tumors of Childhood; Immunotherapy; Autologous Bone Marrow Transplantation

Languages Spoken

MD, Harvard Medical School; PhD, Harvard University


Stanford University Medical Center


Stanford University Medical Center

Board Certifications

Pediatrics; Pediatric Hematology-Oncology

See My Colleagues in:
Publications by Nai-Kong V. Cheung
Visit PubMed for full listing of Nai-Kong V. Cheung journal articles
Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.
View Nai-Kong V. Cheung's laboratory research.